Ynvisible Interactive receives supply LOI from Sapphiros

Executive Summary

• Ynvisible Interactive Inc. received a letter of intent from Sapphiros to become the exclusive supplier of its e‑paper displays for Sapphiros’s next‑generation lateral flow and molecular diagnostic tests.
• The LOI outlines a three‑year exclusive supply agreement, with commercial sales expected to commence in 2026 and accelerate thereafter.
• This partnership marks Ynvisible’s first large‑scale entry into the high‑volume medical diagnostics market, potentially unlocking significant revenue growth.

Key Details

• Letter of Intent (LOI): Received from privately held consumer diagnostics company Sapphiros; outlines intent to enter a three‑year exclusive supply agreement for Ynvisible e‑paper displays.
• Regulatory Status: Clinical studies for Sapphiros’s digital lateral flow tests are ongoing; regulatory approvals pending.
• Commercial Timeline: Initial sales of Ynvisible displays to Sapphiros expected in 2026, with acceleration throughout the year as products launch commercially.
• Scope of Supply: Exclusive provision of ultralow‑power, thin, flexible e‑paper displays for both point‑of‑care and direct‑to‑consumer diagnostic platforms (respiratory and other rapid tests).
• Strategic Significance: First commercial business for Ynvisible in the global medical diagnostics sector; anticipated expansion to additional customers within this market.
• Joint Development History: Collaboration began in 2024, during which Ynvisible engineered customized display solutions for Sapphiros’s diagnostic platforms.
• Market Opportunity: High‑volume medical and diagnostic applications are expanding as healthcare systems adopt decentralized testing; Ynvisible’s technology is positioned to meet low‑power, cost‑sensitive requirements.

Notable Quotes

• “This letter of intent represents an important step toward commercial deployment of Ynvisible's technology in next‑generation diagnostic devices,” – Ramin Heydarpour, CEO & Chairman, Ynvisible Interactive Inc.
• “Our partnership with Ynvisible empowers users of our diagnostic devices…with clear, visible results, offering confidence in understanding test outcomes,” – Mark Gladwell, CEO, Sapphiros.